Application of Medical Moisture Retention Cream (ALHYDRANÃÂ®), A New Option in the Treatment of Venous Eczema
- *Corresponding Author:
- Rondas AALM
Maastricht University, Department of HSR - CAPHRI
Care and Public Health Research Institute, Maastricht
Kentstraat 20, 6137 JT Sittard, The Netherlands
E-mail: [email protected]
Received Date: Jan 23, 2017; Accepted Date: Feb 07, 2017; Published Date: Feb 09, 2017
Citation: Rondas AALM, Schols JMGA (2017) Application of Medical Moisture Retention Cream (ALHYDRAN®), A New Option in the Treatment of Venous Eczema. J Gerontol Geriatr Res 6:395. doi:10.4172/2167-7182.1000395
Copyright: ©2017 Rondas AALM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Aim: Patients with venous eczema may suffer considerably from redness, crusts, pain, flaking and itching. In general, as treatment, compression therapy and indifferent ointments/crèmes are used, often together with topical steroids, though the latter may exhibit considerable side effects. This study aims to explore the effect of Medical Moisture Retention Cream (MMRC = ALHYDRAN®) on the symptoms and complaints of patients suffering a venous eczema, often next to an existing VLU. The working mechanism of MMRC involves a combination of the moisturizing effect of Aloe Vera gel and the moderate occlusion effect of added fatty acids.
Method: In an open case series, 18 patients attending an outpatient wound clinic with moderate venous eczema (maximum TIS score<3) participated. MMRC was applied twice a day and its use was clinically assessed for 4 consecutive weeks. Next to the registration of patient characteristics and capturing the clinical details of the skin lesions in weekly pictures, a VAS scale to assess the patients’ and caregivers’ experience with the treatment was used.
Results: During the application of MMRC, the signs and symptoms of a dry, itchy, scaly, crusty and erythematous skin, fainted in all patients. The skin condition of most participating patients improved and there was also a visibly better skin hydration status in all patients. Relevant aspects such as ‘night rest’, ‘mood’ and ‘social participation’ improved, except for 2 patients. The clinical skin condition of one of these deteriorated in a week, which was not related to the use of MMRC. No side effects to the use of MMRC were observed. The wound care experienced nurses assessed MMRC as effective and feasible.
Conclusion: This study shows that MMRC is effective, safe, and feasible in the treatment of venous eczema. Future Randomized Controlled Trials are necessary to compare the efficacy and feasibility of MMRC with the application of other hydrating creams/ointments and topical steroids.